» Articles » PMID: 12018902

K-ras Mutations in Sporadic Colorectal Tumors in Israel: Unusual High Frequency of Codon 13 Mutations and Evidence for Nonhomogeneous Representation of Mutation Subtypes

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2002 May 23
PMID 12018902
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is one of the most common malignancies in the western world, including Israel. An important step in progression includes induction of activating mutations in the protooncogene K-ras. This event is very frequent and is detected in about 40% of colorectal carcinomas. Previous studies of a variety of genetic disorders revealed unique gene mutation prevalence in Jewish populations, attributed both to differences in genetic background and to variability in environmental exposure. To determine the incidence and molecular subtypes of K-ras mutations in colorectal cancer in Israel, compared with other countries, DNA was isolated from a random collection of 105 colorectal carcinoma samples, and K-ras mutations were detected by an improved designed RFLP and direct sequencing. K-ras sporadic mutations in colorectal cancer in Israel are relatively frequent, with a higher fraction in codon 13 than reported thus far. Comparison with other countries shows a vast heterogeneity in terms of the relative abundance of the affected K-ras codon and in type and representation of specific mutations. The heterogeneous distribution found may be due to a variable genetic background and different environmental factors involved in the initiation and propagation of sporadic colorectal cancer.

Citing Articles

Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.

Benmokhtar S, Laraqui A, Hilali F, Bajjou T, El Zaitouni S, Jafari M Clin Med Insights Oncol. 2024; 18:11795549241255651.

PMID: 38798959 PMC: 11128178. DOI: 10.1177/11795549241255651.


Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer - From the Body Fluid to Tissue Level.

He J, Wu F, Han Z, Hu M, Lin W, Li Y Front Oncol. 2021; 11:632834.

PMID: 33996548 PMC: 8118670. DOI: 10.3389/fonc.2021.632834.


Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification.

Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P Oncol Rep. 2020; 43(4):1187-1198.

PMID: 32323802 PMC: 7058009. DOI: 10.3892/or.2020.7511.


Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.

Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M Int J Mol Sci. 2017; 18(1).

PMID: 28106826 PMC: 5297828. DOI: 10.3390/ijms18010197.


Colorectal Cancer Biomarkers: Where Are We Now?.

Gonzalez-Pons M, Cruz-Correa M Biomed Res Int. 2015; 2015:149014.

PMID: 26106599 PMC: 4461726. DOI: 10.1155/2015/149014.


References
1.
Oudejans J, Slebos R, Zoetmulder F, Mooi W, Rodenhuis S . Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991; 49(6):875-9. DOI: 10.1002/ijc.2910490613. View

2.
Burmer G, Rabinovitch P, Loeb L . Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ Health Perspect. 1991; 93:27-31. PMC: 1568060. DOI: 10.1289/ehp.919327. View

3.
Nigro J, Cho K, Fearon E, Kern S, Ruppert J, Oliner J . Scrambled exons. Cell. 1991; 64(3):607-13. DOI: 10.1016/0092-8674(91)90244-s. View

4.
Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M . Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology. 2000; 118(6):1045-50. DOI: 10.1016/s0016-5085(00)70357-x. View

5.
Tobi M, Luo F, Ronai Z . Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst. 1994; 86(13):1007-10. DOI: 10.1093/jnci/86.13.1007. View